Benralizumab Shows Non-Inferiority to Mepolizumab in Treating EGPA
- Why do Indian Generic Drug Manufacturers Repeatedly Receive Warning Letters from FDA?
- Can Gene Therapy Provide a Cure for HIV?
- More Lethal than Ebola: Germany on High Alert over Marburg Virus Scare
- WHO Approves First Global Monkeypox Vaccine for Adolescents
- Half of Sepsis Patients Die Within Two Years
- Fatigue as the Primary Symptom of Long COVID
Benralizumab Shows Non-Inferiority to Mepolizumab in Treating EGPA
- Can Gene Therapy Provide a Cure for HIV?
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Benralizumab Shows Non-Inferiority to Mepolizumab in Treating EGPA. 59% of patients relieved, AstraZeneca monoclonal antibody Phase 3 trial featured in NEJM
Benralizumab is a monoclonal antibody that binds to IL-5Rα expressed on the surface of eosinophils. By binding to IL-5Rα, it can recruit natural killer cells to rapidly clear these cells by inducing eosinophil apoptosis.
Benralizumab is AstraZeneca’s first biologic for respiratory diseases, approved as an adjunct therapy for severe eosinophilic asthma.
On February 23, 2024, the New England Journal of Medicine published a study titled “Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.”
The study showed that in inducing remission or treating refractory eosinophilic granulomatosis with polyangiitis (EGPA) patients, benralizumab is not inferior to mepolizumab.
This is reportedly the first head-to-head trial of biologics for the treatment of EGPA patients, and the first trial to demonstrate that biologics targeting eosinophils can achieve remission in more than half of patients.
The study compared the efficacy of benralizumab with the IL-5 monoclonal antibody Nucala (mepolizumab) in treating EGPA patients, with patients randomly assigned to receive a single 30 mg subcutaneous injection of benralizumab or 300 mg subcutaneous injection of active control.
Results showed that the trial met its primary endpoint, with benralizumab demonstrating non-inferiority to the active control in treating EGPA patients. At weeks 36 and 48, the adjusted remission rate for the benralizumab group in the primary endpoint was 59%, compared to 56% in the active control group.
Paper link:
DOI: 10.1056/NEJMoa2311155
Benralizumab Shows Non-Inferiority to Mepolizumab in Treating EGPA
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
